Hexima Investor Updates

Chairman and CEO update

It is our pleasure to report on an exciting year at Hexima, during which we progressed our lead drug candidate, HXP124, into first-in-human clinical trials. This is a pivotal step in the development of HXP124 as a safe and effective treatment for fungal nail...

read more

Closing Share Price at 30 June 2018

Shares in Hexima Limited are not traded on the ASX.  The last off-market transfer of shares registered by the Company, as at the close of business on 30 June 2018, was at the price of $0.08 per share. Download a copy of this announcement...

read more